vTv Therapeutics Inc Dossier - Source-backed chat

vTv Therapeutics Inc

VTVTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.53

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $30.84Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $121.9M

Enterprise Value $35.3M

Shares Outstanding 4M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

vTv Therapeutics is a late-stage biopharmaceutical company whose investment thesis centers on its lead candidate, cadisegliatin (TTP399), a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D). With FDA Breakthrough Therapy Designation and a clinically de-risked profile from Phase 1/2 studies showing reduced hypoglycemia and improved HbA1c, cadisegliatin addresses a massive unmet need. The company's balance sheet is highly secure, with $98.1 million in cash as of Q1 2026, bolstered by a recent $20.0 million non-dilutive licensing payment from Newsoara. This provides a clear runway past the critical Phase 3 CATT1 topline data readout expected in the second half of 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$44.00

Mean target$54.33

High · most bullish analyst$67.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$36.2915%

The Phase 3 CATT1 trial fails to meet its primary endpoint of reducing hypoglycemic events, or reveals safety concerns that lead to regulatory delays or another clinical hold. Cash burn accelerates, forcing dilutive financing as the clinical runway shortens without a clear path to commercialization.

Base CaseCentral scenario

$54.3360%

Matches the consensus mean

The Phase 3 CATT1 trial completes enrollment in Q3 2026 and delivers positive topline results in 2H 2026, consistent with Phase 2 SimpliciT-1 data. The company utilizes its strong cash position ($98.1 million as of Q1 2026) to prepare a New Drug Application (NDA) submission. Wall Street consensus remains highly favorable, with the stock trading close to the average analyst target of $54.80.

Bull CaseUpside scenario

$67.0025%

Cadisegliatin's Phase 3 CATT1 trial meets its primary endpoints with high statistical significance, demonstrating a substantial reduction in level 2 and 3 hypoglycemic events and improved glycemic control. The FDA grants rapid approval, making it the first oral adjunctive therapy for T1D in the U.S. and capturing a significant share of the 1.6 million patient market. Partnered programs (such as the PDE4 inhibitor HPP737 and regional T2D trials) trigger substantial milestone payments, driving the stock toward the high-end analyst target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Lead asset cadisegliatin has FDA Breakthrough Therapy Designation and addresses a major unmet need as a potential first-in-class oral adjunctive therapy for T1D.
Strong liquidity position with $98.1 million in cash as of March 31, 2026, providing a runway well past the anticipated 2H 2026 CATT1 topline data readout.
Non-dilutive funding validated by strategic partnerships, including a recent $20.0 million upfront payment from Newsoara for global rights to PDE4 inhibitor HPP737.

Key Investment Risks

Clinical trial execution risk, as the company's valuation is heavily tied to the success of the single Phase 3 CATT1 trial.
Regulatory risks inherent in late-stage drug development, including potential FDA delays or requirements for additional safety studies.
No current commercial product revenues, making the company dependent on licensing milestones and capital markets for long-term funding.

Thesis Invalidation Triggers

Failure of the Phase 3 CATT1 trial to meet its primary efficacy or safety endpoints.
Unexpected clinical holds or regulatory roadblocks imposed by the FDA on cadisegliatin.
Severe delays in patient enrollment for the CATT1 trial extending past Q3 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.